Summary
This Series article synthesises current knowledge on fluid biomarkers (CSF and blood) in multiple sclerosis, examining their role in disease diagnosis, prognosis prediction, and treatment monitoring. The authors highlight recent advances in detecting brain-derived proteins in blood as enablers of efficient longitudinal monitoring, whilst identifying practical challenges and offering recommendations for optimising their clinical utility and enabling personalised patient management.
Regional applicability
This is a clinical neurochemistry review with international scope; whilst not UK-specific, the recommendations on biomarker implementation would be applicable to UK clinical practice and NHS MS services seeking to adopt these paraclinical tools.
Key measures
CSF biomarkers; blood biomarkers; brain-derived proteins; MRI findings; disease relapse risk; disability accrual
Outcomes reported
The article reviews cerebrospinal fluid and blood biomarkers for MS diagnosis, prognosis, disease monitoring and treatment guidance. It discusses advances in detecting brain-derived proteins in blood and identifies challenges in real-world clinical application.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.